Houston, TX · Founded 2015 · Privately Held (backing)
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. OncoResponse is based in Houston, TX and was founded in 2015. Its last reported valuation was $36 million in May 2023. It has raised $180 million across 2 recorded rounds; the latest was a $6 million early-stage round in Apr 2025.
Last reported valuation
$36.0M
Oct 2026
Priced at
—
Total raised
$180.0M
Last round
Early Stage VC
Apr 2025
Team — not yet on record
No current team members for OncoResponse are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of OncoResponse with a free account
·The complete investor list: 25 names
·Watch OncoResponse: the Monday email on marks, rounds and moves
